Stockholm, 20 May 2016. Nuevolution’s Chief Executive Officer, Alex Haahr Gouliaev, provided an overview of the company, and gave an update on the company’s pipeline programs and partnering activities at Avanza Bank’s Börsdag in Stockholm and at Aktiespararna’s Aktiedag in Gothenburg in Wednesday 18 May. A replay of the presentation (in English) in Stockholm can be found on: http://cloud.magneetto.com/wonderland/2016_0518_Nuevolution/view A replay of the presentation (in English, but Q&A in Swedish and English) in Gothenburg can be found on: https://youtu.be/lhHZZuienAk For more information, please contact: Alex Haahr Gouliaev, CEO Phone: +45 7020 0987 Email: ahg@nuevolution.com Henrik D. Simonsen, CFO Phone: +45 3913 0947 Email: hs@nuevolution.com About Nuevolution Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its proprietary discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno -oncology. Nuevolution AB (publ) is required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was sent for publication on Friday 20 May 2016, 12:00 (CET). Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm, Sweden (ticker: NUE). Västra Hamnen Corporate Finance AB acts as Certified Adviser to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com
Replay of two investor presentations available
| Source: Nuevolution AB
Attachments
